Oculopharyngeal muscular dystrophy

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Oculopharyngeal muscular dystrophy
Autosomal dominant - en.svg
Autosomal dominant in majority of cases (autosomal recessive minority)
Classification and external resources
Specialty neurology
ICD-10 G71.0
OMIM 164300
DiseasesDB 29869
MeSH D039141
GeneReviews

Oculopharyngeal muscular dystrophy (OPMD) is a rare form of muscular dystrophy with symptoms generally starting when an individual is 40 to 50 years old. It can be autosomal dominant neuromuscular disease or autosomal recessive. The most common inheritance of OPMD is autosomal dominant, which means only one copy of the mutated gene needs to be present in each cell. Children of an affected parent have a 50% chance of inheriting the mutant gene.[1]

Autosomal dominant inheritance is the most common form of inheritance. Less commonly, OPMD can be inherited in an autosomal recessive pattern, which means that two copies of the mutated gene need to be present in each cell, both parents need to be carriers of the mutated gene, and usually show no signs or symptoms. The PABPN1 mutation contains a GCG trinucleotide repeat [2]at the 5' end of the coding region, and expansion of this repeat which then leads to autosomal dominant oculopharyngeal muscular dystrophy (OPMD) disease.[3][4]

Signs and symptoms[edit]

Lateral rectus Trochlea of superior oblique Superior oblique Superior oblique Superior rectus Superior rectus Superior rectus Oculomotor nerve Oculomotor nerve Optic nerve Optic nerve Optic nerve Annulus of Zinn Inferior oblique Inferior rectus Inferior rectus Medial rectus Optic nerve Optic nerve Optic nerve Optic nerve Medial rectus Medial rectus Ciliary ganglion Oculomotor nerve Globe (human eye) Iris Pupil Anterior chamber Lateral rectus Levator palpebrae superioris muscle Superior oblique Superior oblique Optic nerve Medial rectus Orbit Orbit Orbit
Extraocular muscles are shown in this image of the left eye (lateral view). Click on the structures for more information.

In terms of the signs (and symptoms) of oculopharyngeal muscular dystrophy would be consistent with the following:[1][5]

Though the aforementioned signs/symptoms are the most common, there have been cases though rare, where the peripheral nervous system has had involvement with significant reduction of myelinated fibers [1]

In homozygous cases, this muscular dystrophy is severe and starts earlier in the affected individuals life.[5]

Genetics[edit]

PABN1

The genetics of this type of muscular dystrophy revolve around the PABPN1 gene. This gene suffers mutations that cause the PABPN1 protein to have extra alanine (amino acids), this manifests itself physically in the symptoms of this MD.[4]

The expansion caused by the mutations on the PABPN1 gene ultimately interrupts the cellular mechanics of poly(A) RNA. In most cases oculopharyngeal muscular dystrophy is inherited via autosomal dominance.[6]

The alleles, which are a variant form of a gene[7] involved in this form of MD are: PABPN1, (GCG)n EXPANSION, (GCG)8-13,PABPN1, (GCG)n EXPANSION, (GCG)7 and PABPN1, GLY12ALA.[2]

Diagnosis[edit]

The diagnosis of oculopharyngeal muscular dystrophy can be done via two methods, a muscle biopsy or a blood draw with genetic testing for GCG trinucleotide expansions in the PABPN1 gene. The genetic blood testing is more common.Additionally, a distinction between OPMD and myasthenia gravis or mitochondrial myopathy must be made, in regards to the differential diagnosis of this condition.[1]

Treatment[edit]

Currently no cure or specific treatment exists to eliminate the symptoms or stop the disease progression. A consistent diet planned with the help of a dietitian along with exercises taught by a speech therapist can assist with mild symptoms of dysphagia. Surgical intervention can also help temporarily manage symptoms related to the ptosis and dysphagia. Cutting one of the throat muscles internally, an operation called cricopharyngeal myotomy, can be one way to ease symptoms in more severe cases.[medical citation needed]

Physical therapy and specifically designed exercises may assist with proximal limb weakness, though there is still no current definitive data showing it will stop the progress of the disease. Many of those affected with the proximal limb weakness will eventually require assistive devices such as a wheelchair. As with all surgical procedures, they come with many risk factors.[8][9] In regards to the prognosis of the individual, the life expectancy is not affected by OPMD, however quality of life can be severely impacted. There is also an increased mortality risk from aspiration pneumonia and malnutrition related to the dysphagia.[10]

Epidemiology[edit]

The disease is found across 5 continents (30 countries) and is frequently seen in French Canadians, with a prevalence 1:1000. OPMD affects males and females equally, and affected individuals have been found in Europe (France), Jewish Ashkenazi, and Spanish Americans.[11]

See also[edit]

References[edit]

  1. ^ a b c d Trollet, Capucine; Gidaro, Teresa; Klein, Pierre; Périé, Sophie; Butler-Browne, Gillian; Lacau St Guily, Jean (1993-01-01). Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora JH; Bird, Thomas D.; Fong, Chin-To; Mefford, Heather C., eds. Oculopharyngeal Muscular Dystrophy. Seattle (WA): University of Washington, Seattle. PMID 20301305. update 2014
  2. ^ a b "OMIM Entry - * 602279 - POLYADENYLATE-BINDING PROTEIN, NUCLEAR, 1; PABPN1". www.omim.org. Retrieved 2016-05-29. 
  3. ^ http://www.ncbi.nlm.nih.gov/gene/8106 "PABPN1 poly(A) binding protein, nuclear 1 [ Homo sapiens (human) ]"]11 OCT 2014.
  4. ^ a b Reference, Genetics Home. "oculopharyngeal muscular dystrophy". Genetics Home Reference. Retrieved 2016-05-28. 
  5. ^ a b "Oculopharyngeal muscular dystrophy" (PDF). Retrieved 28 May 2016. 
  6. ^ "OMIM Entry - # 164300 - OCULOPHARYNGEAL MUSCULAR DYSTROPHY; OPMD". www.omim.org. Retrieved 2016-05-29. 
  7. ^ Reference, Genetics Home. "What is a gene?". Genetics Home Reference. Retrieved 2016-05-29. 
  8. ^ Davies, Janet E.; Berger, Zdenek; Rubinsztein, David C. (2006-01-01). "Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder". The International Journal of Biochemistry & Cell Biology. 38 (9): 1457–1462. doi:10.1016/j.biocel.2006.01.016. ISSN 1357-2725. PMID 16530457.  – via ScienceDirect (Subscription may be required or content may be available in libraries.)
  9. ^ Abu-Baker, Aida; Rouleau, Guy A. (1 February 2007). "Oculopharyngeal muscular dystrophy: Recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1772 (2): 173–185. doi:10.1016/j.bbadis.2006.10.003. Retrieved 29 May 2016. 
  10. ^ Choices, NHS. "Muscular dystrophy - Types - NHS Choices". www.nhs.uk. Retrieved 29 May 2016. 
  11. ^ "Oculopharyngeal muscular dystrophy | Disease | Your Questions Answered | Genetic and Rare Diseases Information Center (GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 2016-05-29. 

Further reading[edit]

External links[edit]